Investigation of clonidine and lofexidine for the treatment of barbiturate withdrawal in mice
- PMID: 4082462
Investigation of clonidine and lofexidine for the treatment of barbiturate withdrawal in mice
Abstract
This study was designed to determine the effectiveness of clonidine (CL) and CL analogue, lofexidine (LF), in reducing the incidence and/or severity of convulsion associated with barbiturate withdrawal in mice. CL and LF have been shown to be useful in blocking opioid withdrawal symptoms in rodents and man. Some of the symptoms and possibly the mechanism(s) of the barbiturate withdrawal syndrome are similar to those of the opioid withdrawal syndrome. Therefore, we hypothesized that LF and CL may be efficacious in treating barbiturate withdrawal. The method of Belknap et al as modified by Blum et al for inducing barbiturate dependence in mice was used. Phenobarbital was thoroughly mixed with the animals' milled diet. After 10 days 45 pre-treated mice were divided into withdrawal, control, clonidine- and lofexidine-treated groups. Withdrawal scores were graded as 0 = no effect, 1 = tremor, 2 = wild running, 3 = tonic-clonic seizures, 4 = death, and were collected for each group every 5 hr for 2.5 days. The data in this model suggest that CL and LF offer no protective effect in treating barbiturate withdrawal-induced seizures in mice.
Similar articles
-
Treatment of the barbiturate abstinence syndrome.Med J Aust. 1986 Nov 3;145(9):456-8. Med J Aust. 1986. PMID: 3773832
-
Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects.J Clin Psychiatry. 1983 Sep;44(9):335-7. J Clin Psychiatry. 1983. PMID: 6355070 Clinical Trial.
-
Barbiturate physical dependence in mice: effects on body temperature regulation.J Pharmacol Exp Ther. 1981 Sep;218(3):647-52. J Pharmacol Exp Ther. 1981. PMID: 7196449
-
Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):145-152. doi: 10.1016/j.japh.2019.10.004. Epub 2019 Nov 29. J Am Pharm Assoc (2003). 2020. PMID: 31791720
-
Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.Ann Pharmacother. 2019 Jul;53(7):746-753. doi: 10.1177/1060028019828954. Epub 2019 Feb 6. Ann Pharmacother. 2019. PMID: 30724094 Review.
Cited by
-
Characterization and validation of a spontaneous acute and protracted oxycodone withdrawal model in male and female mice.Pharmacol Biochem Behav. 2024 Sep;242:173795. doi: 10.1016/j.pbb.2024.173795. Epub 2024 Jun 2. Pharmacol Biochem Behav. 2024. PMID: 38834159 Free PMC article.